Nursing Process Focus: Patients Receiving Levodopa (Larodopa)
|
|
- Bernice Lester
- 6 years ago
- Views:
Transcription
1 Assessment Prior to administration: Obtain complete health history including allergies, drug history and possible drug interactions. Obtain baseline evaluation of severity of Parkinson s disease to determine medication effectiveness. Obtain baseline vital signs, especially blood pressure and pulse Nursing Process Focus: Patients Receiving Levodopa (Larodopa) Potential Nursing Diagnoses Risk for Falls Deficient Knowledge, related to drug effects and side effects Impaired Mobility Self-Care Deficit: Bathing/Hygiene, Feeding, Toileting, related to disease process Constipation Planning: Patient Goals and Expected Outcomes Patient will Report increased ease of movement and decreased symptoms of Parkinson s disease Demonstrate an understanding of the drug s action by accurately describing drug side effects and precautions, and measures to take to decrease any side effects Immediately report side effects and adverse reactions Adhere to the drug regimen Implementation Interventions and (Rationales) *Monitor vital signs closely when levodopa dose is being adjusted. (Hypotension could occur as result of dose adjustment. Dysrhythmias can occur in patients predisposed to cardiac problems.) *Provide for patient safety. (Orthostatic hypotension may occur.) *Monitor for behavior changes. (Use of levodopa increases risk of depression or suicidal thoughts, as well as causes other mood disturbances such as aggressiveness and confusion.) *Monitor for symptoms of overdose. Muscle twitching and blepharospasm are early symptoms. *Monitor for improved functional status followed by a loss of therapeutic effects (onoff phenomenon), due to changes in dopamine levels that may last only minutes, or days. Usually occurs in patients on long-term levodopa therapy Patient Education/Discharge Planning Instruct patient or caregiver to: *report signs of hypotension, dizziness, lightheadedness, feelings that heart is racing or skipping beats, or dyspnea *have routine EKGs and vital signs taken * to change position slowly and to resume normal activities slowly * how to protect self from falls Instruct patient or caregiver: *watch for and report immediately any signs of changes in behavior or mood *counseling or a support group may help deal with these feelings; assist patient to find such resources if needed *Instruct patient or caregiver to be aware of newly occurring muscle twitching, including muscles of eyelids and to report immediately *Instruct patient or caregiver to report rapid, unpredictable changes in motor symptoms to health care provider immediately, and that this can be corrected with changes in levodopa dosage schedule.
2 *Evaluate diet. (Absorption of levodopa decreases with high protein meals or high consumption of pyridoxine-containing foods.) *Monitor glucose levels in patients with diabetes mellitus. (Loss of glycemic control may occur in diabetic patient.) *Monitor for decreased kidney or liver function. (Decrease in these functions may slow metabolism and excretion of levodopa, possibly leading to overdose or toxicity.) *Monitor for side effects in the elderly. (Elderly patients may experience more rapid and severe side effects, especially those affecting cardiovascular system.) *Monitor for other drug-related changes. (Levodopa may cause urine and perspiration to darken in color, but it is not a sign of overdose or toxicity) Instruct patient to: * take on empty stomach, but food may be eaten 15 minutes after, to decrease GI upset *avoid taking levodopa with high protein meals *avoid high consumption of foods containing vitamin B 6 (pyridoxine) (bananas, wheat germ, green vegetables, liver, legumes). *watch for vitamin B 6 in multivitamins, fortified cereals, and antinauseants, so these products should be avoided *how to read food, OTC medication labels Instruct diabetic patient to: *consistently monitor blood glucose both by self and with periodic lab studies. *report symptoms of hypo- or hyper-glycemia *Advise patient to have liver function tests and kidney function tests prior to beginning levodopa therapy and periodically during therapy *Instruct elderly patients to report any symptoms involving cardiovascular system: changes in heart rate, dizziness, faintness, edema, palpitations *Inform patient that urine may darken and sweat may be dark colored, but not to be alarmed Evaluation of Outcome Criteria Evaluate the effectiveness of drug therapy by confirming that patient goals and expected outcomes have been met (see Planning ).
3 Assessment Prior to administration: Obtain complete health history including allergies, drug history and possible drug interactions. Obtain baseline of severity of Parkinson s symptoms to determine effectiveness. Assess for use of other medications. Obtain lab work to include a complete blood count, liver and renal function studies. Obtain baseline vital signs, especially pulse. Nursing Process Focus: Patients Receiving Benztropine (Cogentin) Potential Nursing Diagnoses Risk for Constipation, related to side effects of drug Risk for Injury, related to effects of drug Risk for Imbalanced Body Temperature Disturbed Sleep Pattern, insomnia or extreme drowsiness related to action of drug Ineffective Therapeutic Regimen Management Urinary Retention, related to side effect of drug Planning: Patient Goals and Expected Outcomes Patient will Experience relief of Parkinson s symptoms or EPS due to anti-psychotic drugs. Immediately report any occurrence of adverse reactions. Demonstrate an understanding of the drug s action by accurately describing drug side effects and precautions, and measures to take to decrease any side effects. Maintain compliance with drug regimen. Maintain normal bowel pattern. Implementation Interventions and (Rationales) *Monitor adherence to recommended therapy. Benztropine should be begun with low dose, then gradually increased. *Monitor proper storage of benztropine. *Monitor environmental temperature. (Patient will have decreased ability to tolerate heat, and may develop heat stroke.) *Monitor patient s ability to void, as well as intake and output. (Benztropine can cause urinary hesitation or retention, secondary to its anticholinergic effect.) *Evaluate medication regimen for drugs that interact with benztropine. (Concurrent use of phenothiazines causes increased risk of adverse Patient Education/Discharge Planning *to take benztropine as ordered, unless side effects occur; then notify health care provider. *that it usually takes 2-3 days before desired effect will be noticed. *Advise patient to store benztropine in tightly covered, light-resistant container at moderate room temperature. *Advise patient to avoid strenuous activity in hot weather, to plan rest periods, and to avoid strenuous activity during heat of day to decrease risk of heat stroke. *to report infrequent voiding, or feeling of fullness after emptying the bladder. *to keep a record of intake and output with times of occurrence, and to report imbalance in intake and output. to disclose any history of psychiatric problems or other medication use to all
4 anticholinergic effects; patient will need decreased phenothiazine dose, and close monitoring for worsening symptoms of psychiatric disorder.) *Monitor drug use in elderly. (Increased sedative effects of benztropine may occur and lower doses may be needed.) *Monitor for anticholinergic effects such as dry mouth. *Observe for increased symptoms of Parkinson s or EPS. (If involuntary movements or increased rigidity occur, medication levels may not be therapeutic.) *Monitor for constipation and for signs of paralytic ileus. (This may be caused by decreased GI motility due to drug s anticholinergic effects.) *Observe for unsafe activities. (Benztropine may cause sedation or dizziness.) health care providers to report urinary problems, blurred vision, constipation, dry skin, nausea, vomiting, drowsiness, dysphagia, photophobia *Advise patient to report any drowsiness. *Teach patient measures to use: sugarless hard candy or gum, frequent drinks of water, frequent rinsing of mouth. Review with patient and family: exactly how to take medication. to report increased muscle rigidity, difficulty changing position, muscle spasms or other involuntary movements. Advise patient: to take benztropine after meals to decrease GI irritation. to decrease constipation by increasing fluids, fruits and vegetables, exercise if possible. to report signs of paralytic ileus (abdominal pain, intermittent constipation, abdominal distention, nausea, and vomiting.) Instruct family: to supervise ambulation until response to medication is known Advise patient not to drive until response to medication is known *Monitor for symptoms of overdose. *Advise patient to report immediately: (Some adverse reactions may result from hallucinations, confusion, disorientation, atropine-like toxicity, and may be eliminated by delusions, anxiety, hyperthermia, tachycardia, lowering dose of benztropine.) increased respirations. Evaluation of Outcome Criteria Evaluate the effectiveness of drug therapy by confirming that patient goals and expected outcomes have been met (see Planning ).
5 Assessment Prior to administration: Severity of Alzheimer s disease as baseline in order to determine effectiveness. Use of other medications, especially anticholinergics, NSAIDS, carbamazepines dexamethasone phytoin phenobarbital or rifampin. Lab work to include a complete blood count, liver and renal function studies. Baseline vital signs, especially blood pressure and pulse. May cause changes in BP and atrial fibrillation. Nursing Process Focus: Patients Receiving Donepezil (Aricept) Potential Nursing Diagnoses Risk for Injury, related to effects of drug Deficient Knowledge, related to drug action and side effects Impaired Memory, related to ineffective drug therapy Self-Care Deficit: Bathing/Hygiene, Feeding, Toileting, related to disease process Compromised Family Coping, related to ineffective drug therapy Planning: Patient Goals and Expected Outcomes Patient will Experience improved cognitive functioning and memory. Demonstrate an understanding of the drug s action by accurately describing drug side effects and precautions, and measures to take to decrease any side effects. Adhere strictly to the recommended treatment. Immediately report any occurrence of any adverse reactions Demonstrate ability to complete ADLs Implementation Interventions and (Rationales) *Investigate any other conditions patient may have that could be mistaken for Alzheimer s disease: electrolyte imbalances, dehydration, psychiatric disorder, adverse reaction to a medication, or other metabolic problem. *Evaluate for COPD or asthma. (Must be used cautiously if they exist; may further decrease diameter of bronchioles, thus decreasing already compromised air exchange.) *Evaluate for cardiovascular problems. (Donepezil may cause bradycardia secondary to vagotonic effects on heart, especially if patient also has conduction abnormalities.) *Monitor for safety. (Donepezil may cause dizziness or bradycardia. See previous section regarding assessing for Patient Education/Discharge Planning *Advise patient/family to have complete medical work-up prior to beginning donepezil therapy. *Instruct patient/family on the importance of complete disclosure of all medical conditions. *Instruct patient/family to be aware of and report any signs of bradycardia, faintness, weakness, fatigue, dizziness, light-headedness. Instruct patient/family: to use caution with ambulation and exercise, and to closely supervise patient.
6 cardiovascular problems.) that as disease progresses, patient will become less aware of safety hazards, and family will have to intervene to keep patient safe. *Monitor for seizures. (Donepezil and any other drug in the category of cholinomimetic medications can cause general seizures. Seizures may also be due to Alzheimer s disease itself.) *Monitor for GI problems. (Donepezil may increase gastric acid secretion, leading to increased risk for developing ulcers with resultant GI bleeding. Donezepil may cause anorexia.) *Monitor for side effects/adverse reactions. *Monitor for worsening of symptoms of Alzheimer s disease. (Donepezil is not effective for every patient who takes it; patient may not be taking medication as ordered, or medication may not have reached therapeutic levels; disease may be progressing despite treatment.) *Monitor for symptoms of overdose: severe nausea/vomiting, sweating, salivation, hypotension, bradycardia, convulsions, increased muscle weakness, including *Teach family measures to take to protect patient during seizure activity. Explain to patient and family: that nausea/vomiting/diarrhea may occur with early therapy but usually resolve in 1-3 weeks of continued therapy. measures to counteract any anorexia. to watch for and immediately report signs of GI bleeding, such as black, tarry stools. Instruct family: on symptoms of CNS and musculoskeletal side effects. that CNS changes may be secondary to disease itself, not medication Instruct patient/family: *correct way to take medication *to notify health care provider if no improvement is noticed within 2 weeks. Teach patient and family: symptoms of cholinergic side effects. patient may need to be hospitalized for treatment of overdose. respiratory muscles Evaluation of Outcome Criteria Evaluate the effectiveness of drug therapy by confirming that patient goals and expected outcomes have been met (see Planning ).
Nursing Process Focus: Patients Receiving Chlorpromazine (Thorazine)
Nursing Process Focus: Patients Receiving Chlorpromazine (Thorazine) Potential Nursing Diagnoses Ineffective Therapeutic Regimen Management Risk for Activity Intolerance, related to side effect of drug
More informationInstruct patient and caregivers: Need for constant monitoring Potential complications of drug therapy
Assessment Prior to administration: Assess patient for chest pain, dysrhythmias, and vital signs (initially and throughout therapy) Obtain complete medical history, including allergies, especially heart
More informationChapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis
Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral
More informationNursing Process Focus: Patients Receiving Dextran 40 (Gentran 40)
Assess for presence/history of hypovolemia, shock, venous thrombosis. Assess vital signs: Hypovolemic shock secondary to surgery, burns, hemorrhage, other serious condition PT and PTT abnormalities Venous
More informationNursing Process Focus: Patients Receiving Bethanechol (Urecholine)
Assessment Prior to administration: Assess for urinary retention, urinary patterns (initially and throughout therapy). Obtain complete health history; including allergies, drug history and possible drug
More information*Monitor for significant side effects, especially symptoms of neurological or cardiovascular events.
Assessment Prior to administration: Obtain complete health history including allergies, drug history, and possible drug reactions Assess reason for drug administration such as presence/history of anemia
More informationNURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet)
NURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet) ASSESSMENT Prior to administration: Obtain complete health history including allergies, drug history, and possible drug interactions.
More informationNursing Process Focus: Patients Receiving Phenelzine (Nardil)
Assessment Prior to administration: Obtain complete health history including allergies, neurological, cardiac, renal, biliary, and mental disorders including blood studies: CBC, platelets and liver enzymes.
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationMonitor patient s ability to self-administer insulin. (To evaluate safe administration of drug.)
Nursing Process Focus: Patients Receiving Regular Insulin (Humulin, Novolin) Assessment Prior to administration: Assess any patient allergies. Older forms of insulin are made from beef and pork and may
More informationPresenter. Dr. Ronald Lucchino
Adverse Drug Reactions in Adults with Down Syndrome Presenter Dr. Ronald Lucchino rvluc@comcast.net PURPOSE To increase staff awareness that older adults with DD may have higher levels of medication in
More informationNursing Process Focus: Patients Receiving Salmeterol (Serevent)
Prior to administration: Assess for presence/history of chronic asthma, exercise induced asthma, acute asthma attacks, and acute upper airway obstruction. Assess respiratory rate and lung sounds, pulse
More informationLESSON ASSIGNMENT. Cholinergic Blocking Agents (Anticholinergic Agents).
LESSON ASSIGNMENT LESSON 10 Cholinergic Blocking Agents (Anticholinergic Agents). TEXT ASSIGNMENT Paragraphs 10-1 through 10-4. LESSON OBJECTIVES 10-1. From a list of statements, select the statement that
More informationDrug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)
Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION Pr BACLOFEN Baclofen Tablets 10 mg and 20 mg This leaflet is part III of a three-part "Product Monograph" published when BACLOFEN was approved for sale in Canada and is designed
More informationRaritan Bay Medical Center
Raritan Bay Medical Center For any question regarding Med of the Month. You may contact : Sherr Ann Arabit MSN, RN-BC, CCRN Professional Development Department Ext 4196 1 Professional Development Presents
More informationMonitor vital signs, especially blood pressure. (Diuretics reduce circulating blood volume, resulting in lowered blood pressure.).
Assessment Prior to administration: Obtain complete health history including allergies; cardiac, pulmonary, renal, and biliary disorders including blood studies: CBC, BUN, creatinine, electrolytes, PT,
More informationPRODUCT INFORMATION. (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate
NORGESIC Orphenadrine citrate and paracetamol PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: CAS number: 4682-36-4 Chemical structure: Orphenadrine citrate (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine
More informationChapter Goal. Learning Objectives 9/12/2012. Chapter 36. Geriatrics. Use assessment findings to formulate management plan for geriatric patients
Chapter 36 Geriatrics Chapter Goal Use assessment findings to formulate management plan for geriatric patients Learning Objectives Describe dependent & independent living environments Identify local resources
More informationMedicine purposes and side effects
Medicine purposes and side effects Ace inhibitors Purpose: Relaxes blood vessels and decreases blood volume, which lowers blood pressure and decreases oxygen demand from the heart Side effects: Low blood
More informationPATIENT INFORMATION LEAFLET ZOXADON TABLETS RANGE
SCHEDULING STATUS: S5 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: ZOXADON 0,5 mg: Each tablet contains 0,5 mg risperidone. ZOXADON 1 mg: Each tablet contains 1 mg risperidone. ZOXADON 2 mg: Each
More informationDrugs for Emotional and Mood Disorders Chapter 16
Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,
More informationSTAYING HYDRATED Serious effects of dehydration
STAYING HYDRATED Serious effects of dehydration Belinda Kerr Marketing Director Ashley Piercy Scurry County Extension Agent What percentage of your body is water? 10% 25% 50% 75% 95% Functions of water
More informationNorpramin (desipramine)
Generic name: Desipramine Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets Available in generic: Yes Drug class: Tricyclic antidepressant General Information Norpramin (desipramine)
More informationMedication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber.
Know Your Medicines Duloxetine The purpose of this leaflet is to give you some general information on duloxetine, and is intended as a guide only. This should be read in conjunction with the official patient
More informationCare for patients with Neurological disorders
King Saud University College of Nursing Medical Surgical Department Application of Adult Health Nursing Skills ( NUR 317 ) Care for patients with Neurological disorders Outline; EEG Overview. Nursing Interventions;
More informationChapter 55. Changes in the Airway With COPD. Manifestations of Severe COPD. Drugs Used to Treat Obstructive Pulmonary Disorders
Chapter 55 Drugs Used to Treat Obstructive Pulmonary Disorders Changes in the Airway With COPD Manifestations of Severe COPD Air is trapped in the lower respiratory tract The alveoli degenerate and fuse
More informationMigraleve, Migraleve Pink and Migraleve Yellow Product Information
Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also
More informationTricyclic Antidespressants: Actions
Introductory Clinical Pharmacology Chapter 24 Antidepressant Drugs Tricyclic Antidespressants: Actions Increase sensitivity in postsynaptic alpha (α)-adrenergic, serotonin receptors Decrease sensitivity
More informationElavil (amitriptyline)
Generic name: Amitriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets; 10 mg/ml injection Available in generic: Yes Drug class: Tricyclic antidepressant General Information
More informationPRONUNCIATION: (met-for-min) COMMON BRAND NAME(S): Riomet
PRONUNCIATION: (met-for-min) COMMON BRAND NAME(S): Riomet HOW TO USE: Read the Patient Information Leaflet if available from your pharmacist before you start taking metformin and each time you get a refill.
More informationMcHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Optional Continuing Education 2018 #9 Heat Emergencies
McHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Optional Continuing Education 2018 #9 Heat Emergencies As EMS providers we are called to treat several medical conditions. Heart Attacks,
More informationPamelor (nortriptyline)
Generic name: Nortriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg capsules; 10 mg/5 ml oral solution Available in generic: Yes Drug class: Tricyclic antidepressant General Information Pamelor
More informationMEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets
FDA-Approved Medication Guide MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets Savella is not used to treat depression, but it acts like medicines that are used to treat depression (antidepressants)
More informationSymbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination)
Symbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination) Generic name: Olanzapine and fluoxetine combination Available strengths: 6 mg/25 mg, 6 mg/50 mg, 12 mg/25 mg, 12 mg/50 mg (Zyprexa/Prozac)
More informationIt is used to treat the symptoms of dementia in people diagnosed as having mild to moderately severe Alzheimer s disease.
Package leaflet: Information for the patient Donepezil Hydrochloride 5 mg Film-coated Tablets Donepezil Hydrochloride 10 mg Film-coated Tablets donepezil hydrochloride Read all of this leaflet carefully
More informationPROBABLE HEALTH CONSEQUENCES OF NOT TAKING THIS MEDICATION
University Health System PSYCHIATRIC SERVICES ANTIPSYCHOTICS Atypical Neuroleptics Risperdal (Risperidone ) Olanzapine (Zyprexa ) Quetiapine (Seroquel ) Course of Treatment: PURPOSE AND GENERAL INFORMATION
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationDATA SHEET 1 PRODUCT NAME. Benztropine Omega 1mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
DATA SHEET 1 PRODUCT NAME Benztropine Omega 1mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of sterile clear colourless solution contains: 1 mg of Benztropine mesylate
More informationMedication Information for Parents and Teachers
Medication Information for Parents and Teachers General Information About Medication Hydroxyzine Vistaril Each child and adolescent is different. No one has exactly the same combination of medical and
More informationPRESCRIBING INFORMATION WITH CONSUMER INFORMATION MYDRIACYL. tropicamide ophthalmic solution, USP. 0.5% and 1% w/v.
PRESCRIBING INFORMATION WITH CONSUMER INFORMATION Pr MYDRIACYL tropicamide ophthalmic solution, USP 0.5% and 1% w/v Anticholinergic Alcon Canada Inc. 2665 Meadowpine Blvd. Mississauga, ON L5N 8C7 www.alcon.ca
More informationAripiprazole Accord 5, 10, 15 and 30 mg film-coated tablets
Aripiprazole Accord 5, 10, 15 and 30 mg film-coated tablets EDUCATIONAL MATERIAL FOR THE PATIENTS AND THEIR CAREGIVERS Introduction Your doctor has diagnosed you with bipolar I disorder and prescribed
More informationSymptom Management Challenges at End-of-Life
Symptom Management Challenges at End-of-Life Amanda Lovell, PharmD, BCGP Clinical Pharmacist- Inpatient Units Optum Hospice Pharmacy Services February 15, 2018 Hospice Pharmacy Services Objectives Identify
More informationMEDICATION GUIDE. Quetiapine (kwe-tye-a-peen) Tablets USP
MEDICATION GUIDE Quetiapine (kwe-tye-a-peen) Tablets USP Read this Medication Guide before you start taking quetiapine tablets and each time you get a refill. There may be new information. This information
More informationINTRODUCTION: DEFINITION OF HEAT ILLNESS:
Coastal Carolina University Athletic Training Department Policy and Procedure Manual Exertional Heat Illness Management Fluid Replacement/Rehydration Protocol Revised/Reviewed 3/2013 INTRODUCTION: The
More informationTofranil and Tofranil-PM (imipramine)
Tofranil and Tofranil-PM (imipramine) Generic name: Imipramine Available strengths: 10 mg, 25 mg, 50 mg tablets; 75 mg, 100 mg, 125 mg, 150 mg capsules (Tofranil-PM) Available in generic: Yes Drug class:
More informationTalking to Patients and Their Families
Talking to Patients and Their Families About Clozapine The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office of Mental Health
More informationCOALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION - Medications POLICY NUMBER: 510
COALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION - Medications POLICY NUMBER: 510 Effective Date: August 31, 2006 SUBJECT: CARE OF THE INDIVIDUAL RECEIVING CLOZAPINE 1. GENERAL: Clozapine
More informationPatient/Caregiver Information Brochure For Bipolar I Disorder in Adolescents
Patient/Caregiver Information Brochure For Bipolar I Disorder in Adolescents Date of approval: March 2013 Mercury number: 570HQ13NP00107-01-IE 786203127-001_Patient_Caregiver_IRELAND_v4.indd 1 20/03/2013
More informationXYZAL 5 MG FILM-COATED TABLET
XYZAL 5 MG FILM-COATED TABLET Levocetirizine dihydrochloride Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription. However,
More informationDelirium and Dementia
Delirium and Dementia Elder Friendly Care in Acute Care Seniors Health Strategic Clinical Network Acute Care Stress Blender Poor Poor sleep At-Risk Older Adult TREAT CAUSE immediately & aggressively. Increased
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationPRODUCT INFORMATION. AKINETON (biperiden hydrochloride 2 mg tablets)
PRODUCT INFORMATION AKINETON (biperiden hydrochloride 2 mg tablets) NAME OF THE MEDICINE Non-proprietary name: biperiden hydrochloride Structural formula (biperiden): Chemical name (biperiden): α-5-norbornen-2-yl-α-phenyl-1-piperidine
More informationNursing Process Focus: Patients Receiving Phenobarbital (Luminal)
Assessment Prior to administration: Obtain complete health history, including allergies, neurological, pulmonary, cardiac, renal, biliary, and mental disorders including blood studies: CBC, BUN, creatinine,
More informationCOMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK
COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics
More information1 pt. 2pt. 3 pt. 4pt. 5 pt
Heat Stress Causes Risk Factors Heat Illnesses Treatment Prevention 1pt 1 pt 1 pt 1pt 1 pt 2 pt 2 pt 2pt 2pt 2 pt 3 pt 3 pt 3 pt 3 pt 3 pt 4 pt 4 pt 4pt 4 pt 4pt 5pt 5 pt 5 pt 5 pt 5 pt Causes 1pt Name
More informationYOUR GUIDE TO ARIPIPRAZOLE Patient/Caregiver Information Brochure
YOUR GUIDE TO ARIPIPRAZOLE Patient/Caregiver Information Brochure Aripiprazole Dr. Reddy's 5, 10, 15 and 30 mg film-coated tablets Aripiprazole Dr. Reddy s 1 mg/ml Oral Solution Introduction Your doctor
More informationMEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII)
MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental use by a child is a medical emergency
More informationI. ALL CLAIMS: HEALTH CARE PROFESSIONALS
HCP Prescribing Information Date/Version January 2015 Version 2 Page: 1 of 5 I. ALL CLAIMS: HEALTH CARE PROFESSIONALS Indications and Usage Saxenda (liraglutide [rdna origin] injection) is indicated as
More informationDexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.
Dexamethasone Other Names: Decadron About This Drug Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Possible Side Effects (More Common) Increased
More informationPRODUCT MONOGRAPH. FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION. Anti-inflammatory, Analgesic
0 PRODUCT MONOGRAPH FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION Anti-inflammatory, Analgesic INFORMATION FOR THE PATIENT FLOCTAFENINE, which has been prescribed to you
More informationMEDICATION GUIDE Morphine Sulfate (mor-pheen) (CII) Oral Solution
MEDICATION GUIDE Morphine Sulfate (mor-pheen) (CII) Oral Solution IMPORTANT: Keep Morphine Sulfate Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency and
More informationMEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP
MEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP IMPORTANT: Keep oxycodone hydrochloride oral solution in a safe place away from children. Accidental use by a child is
More informationMedications and the I/DD Population
Medications and the I/DD Population A Supplemental Document to Session 4 in Webinar Series ADR Symptoms that Mimic Age Related/Associated Changes and Diseases Biological Changes Impaired senses Cardiovascular
More information2. Have your symptoms affected your ability to carry out your daily activities? YES NO
QUESTIONNAIRE Page 1 of 5 Date: Referring MD (Name, Address, Phone Number): Primary Care Physician (Name and Address, Phone Number): Reason for visit: 1. How long have you had symptoms? Describe your symptoms?
More informationNausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.
Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine
More informationPackage leaflet: Information for the patient. Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate
Package leaflet: Information for the patient Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate Read all of this leaflet carefully before you start using this medicine because
More informationAVIOMARIN 50 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER AVIOMARIN 50 mg tablets DIMENHYDRINATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationDATE OF BIRTH: MELANOMA INTAKE
MELANOMA INTAKE GENERAL INFORMATION How was your first diagnosed? (Check the diagnosis that describes your condition.) Melanoma Merkel Cell Carcinoma Squamous Cell Carcinoma Basal Cell Carcinoma Other
More informationHave you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider.
Have you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider. 1 Benefits of Clozapine Clozapine may work when other medications don t. Doctors
More informationWeek 2. Purpose: Helps you establish priorities, to get a baseline of the patient to compare to.
Week 2 Functional Health Patterns Purpose: Helps you establish priorities, to get a baseline of the patient to compare to. If patient baseline is 102/70, later is at 140/90. BP is elevated is it because
More informationElements for a Public Summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Schizophrenia Schizophrenia is a mental disorder often characterized by abnormal social behaviour and failure to recognize what
More informationThe Surgical Patient. Objectives:
The Surgical Patient Objectives: 1. Discuss the effect of surgery on the body systems. 2. Explain the etiological factors, nursing assessment, and management of potential problems during the postoperative
More informationMEDICATION GUIDE. Aripiprazole Tablets (AR-i-PIP-ra-zole)
MEDICATION GUIDE Aripiprazole Tablets (AR-i-PIP-ra-zole) What is the most important information I should know about aripiprazole tablets? (For other side effects, also see What are the possible side effects
More informationPlease list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.)
Date: Patient Name: D.O.B Last First M.I History of Present Illness: What is the reason for your visit? Date symptom started? Please list any treatments you have previously had for current illness. (Physical
More informationEU RISK MANAGEMENT PLAN (EU-RMP)
EU RISK MANAGEMENT PLAN (EU-RMP) HYDROXYZINE 25 mg, scored film-coated tablets Active substance(s) (INN or common name): Hydroxyzine hydrochloride Pharmaco-therapeutic group (ATC Code): N05BB01, Anxiolytics
More informationMEDICATION GUIDE Quetiapine Fumarate Extended-Release Tablets (Kwe-TYE-a-peen FUE-ma-rate)
MEDICATION GUIDE Quetiapine Fumarate Extended-Release Tablets (Kwe-TYE-a-peen FUE-ma-rate) Read this Medication Guide before you start taking quetiapine fumarate extended-release tablets and each time
More informationNEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.
1. PRODUCT NAME ACUPAN 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nefopam hydrochloride 30 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
More informationOXYSPAS Tablets (Oxybutynin chloride)
Published on: 10 Jul 2014 OXYSPAS Tablets (Oxybutynin chloride) Composition OXYSPAS-2.5 Tablets Each uncoated tablet contains Oxybutynin chloride... 2.5 mg OXYSPAS-5 Tablets Each uncoated tablet contains
More informationSymptom Review (page 1) Name Date
v2.4, 2/13 JonathanTreasure.com Botanical Medicine & Cancer Herb Drug Interactions Herbalism 3.0 Symptom Review (page 1) Name Date INSTRUCTIONS Please read each section below carefully and, after each
More informationDrugs Affecting the Gastrointestinal System. Antidiarrheal and Laxatives
Drugs Affecting the Gastrointestinal System Antidiarrheal and Laxatives Diarrhea Abnormal frequent passage of loose stools or Abnormal passage of stools with increased frequency, fluidity, and weight,
More informationBroward Oncology Associates, P.A. PATIENT INFORMATION
NAME: BIRTHDATE: AGE: LOCAL ADDRESS (Street city state zip): HOME TELEPHONE# CELL # SOCIAL SECURITY #: - - SEX MARITAL STATUS WHAT IS YOUR HT? WHAT IS YOUR WT? EMPLOYER WORK# SPOUSE'S NAME SPOUSE'S EMPLOYER
More informationThis leaflet answers some common questions about Momex SR Tablets.
Momex SR Modified (Sustained) Release Tablets [Morphine sulphate] CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Momex SR Tablets. It does not contain
More informationPatient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension
Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension Read this Patient Information before you start taking VERSACLOZ and each time you get a refill. There may be new information. This
More informationPATIENT HEALTH QUESTIONNAIRE Radiation Oncology
REVIEWED DATE / INITIALS Safety: Yes No Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: Yes No If YES, please list medication allergies:
More informationPATIENT HEALTH QUESTIONNAIRE Radiation Oncology
REVIEWED DATE / INITIALS Safety: Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: If YES, please list medication allergies: Do you have
More informationWhat is the most important information I should know about Morphine Sulfate Oral Solution?
Medication Guide MORPHINE SULFATE (mor-pheen) (CII) Oral Solution IMPORTANT: Keep Morphine Sulfate Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency and
More informationMEDICATION GUIDE Morphine Sulfate (MOR feen SUL fate) (CII) Oral Solution
MEDICATION GUIDE Morphine Sulfate (MOR feen SUL fate) (CII) Oral Solution IMPORTANT: Keep morphine sulfate oral solution in a safe place away from children. Accidental use by a child is a medical emergency
More informationJOHN MICHAEL ROACH, MD
GASTROENTEROLOGY JOHN MICHAEL ROACH, MD 520 N. 4 TH AVE. PASCO, WA 99301 Phone: (509) 546-8383 Name: Date of Birth: First Middle (full) Last m/d/yr Primary care provider: Referring physician: Local Pharmacy:
More information2:39 2: Dizziness and nausea Cerebral. 2:57 1: Vomiting Gastro-intestinal
Supplemental: Table B: Detailed description of adverse events by time, treatment group and procedure T-spinal to incident T-spinal to PACU discharge Group THA/TKA Adverse event description Adverse event
More information5/18/2017. Specific Electrolytes. Sodium. Sodium. Sodium. Sodium. Sodium
Specific Electrolytes Hyponatremia Hypervolemic Replacing water (not electrolytes) after perspiration Freshwater near-drowning Syndrome of Inappropriate ADH Secretion (SIADH) Hypovolemic GI disease (decreased
More informationShared Care Agreement for Donepezil, Galantamine, Rivastigmine and Memantine
Clinical SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: Date Treatment Started: Name of drug: (Add Date) One copy of information leaflet given to
More informationANTIPSYCHOTICS AGENTS CONVENTIONAL
ANTIPSYCHOTICS AGENTS CONVENTIONAL Documentation A. FDA approved indications 1. Psychotic Disorder (Haloperidol, Thiothixene) 2. Schizophrenia 3. Bipolar Disorder, Manic (Chlorpromazine) 4. Severe Behavioral
More informationNursing Care of the Resident with Diabetes Mellitus
Nursing Care of the Resident with Diabetes Mellitus Level III Definitions Diabetes is a disorder in which there is relative or absolute lack of insulin. Among other things, glucose (sugar) from food cannot
More informationSummary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole)
EMA/370707/2016 Summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma, which details the
More information